Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology
Retrieved on:
Monday, December 21, 2020
The licensing agreement gives Astrea access to the Affimer technology for applications in bioprocessing, expanding its range of ligand discovery and development capabilities to include best-in-class chemical and biological platforms for customer development programs.
Key Points:
- The licensing agreement gives Astrea access to the Affimer technology for applications in bioprocessing, expanding its range of ligand discovery and development capabilities to include best-in-class chemical and biological platforms for customer development programs.
- "Affimer reagents are high-performance proteinaceous ligands that have been engineered for a wide range of applications as superior alternatives to antibody-based ligands.
- The license agreement includes an option that gives Astrea the ability to secure exclusive access to the Affimer technology for applications in bioprocessing.
- The Astrea Bioseparations team expects to begin development of new products based on the technology early in 2021.